Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: -others

Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy

Elisabeth Quoix, et al. ASCO Annual Meeting 2015 – May 29-June 2, 2015 – Chicago, Illinois Download the poster here Poster Presentation

Published 1 June 2015
Categorized as -others, 2015, Publication, TG4010

TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models

Karine Lélu, et al. Journal of Hepatology, April 2015, Volume 62, Supplement 2, Page S205 – Download the article Publication

Published 30 April 2015
Categorized as -others, 2015, Publication, TG1050

TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models

Karine Lélu, et al. EASL Liver Congress 2015, Vienna-23th April 2015 Download the poster here Poster Presentation

Published 30 April 2015
Categorized as -others, 2015, Publication, TG1050

Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer

Poster TG4010-AACR 2015-KR Karola Rittner, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2497 Download the posterhere Poster Presentation

Published 21 April 2015
Categorized as -others, 2015, Publication, TG4010

The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies

Poster MVA VIRAL PLATFORM-AACR 2015-JML Jean-Marc Limacher, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2498. Download the poster here Poster Presentation

Published 21 April 2015
Categorized as -others, 2015, Publication, TG4010

Viral hepatitis: HBV cure—can we pin our hopes on immunotherapy ?

Hung-Chih Yang, et al. Nature Reviews Gastroenterology & Hepatology (2015) doi:10.1038/nrgastro.2015.8 – Download the article Publication

Published 5 February 2015
Categorized as -others, 2015, Publication, TG1050

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.

Martin P, Dubois, et al. Gut. 2014 Nov 26, doi: 10.1136/gutjnl-2014-308041 – Download the article Publication

Published 26 November 2014
Categorized as -others, 2014, Publication, TG1050

TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study

Elisabeth Quoix, et al. Journal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 – Download the article Publication

Published 6 November 2014
Categorized as -others, 2014, Publication, TG4010

TIME: A Phase 2b/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.

ESMO 2014-Poster TG4010 TIME Ph 2b Elisabeth Quoix, et al. ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152 Download the poster here Poster Presentation

Published 30 September 2014
Categorized as -others, 2014, Publication, TG4010

Efficacy of immunotherapy with TG4040, Peg-interferon, and ribavirin in A phase 2 study of patients with chronic HCV infection.

Adrian Di Bisceglie, et al. Gastroenterology, 2014; Mar 18 – Download the article Publication

Published 1 July 2014
Categorized as -others, 2014, Publication, TG4040

Posts pagination

Newer posts Page 1 … Page 9 Page 10 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu